SE9903619D0 - Use and method of treatment - Google Patents

Use and method of treatment

Info

Publication number
SE9903619D0
SE9903619D0 SE9903619A SE9903619A SE9903619D0 SE 9903619 D0 SE9903619 D0 SE 9903619D0 SE 9903619 A SE9903619 A SE 9903619A SE 9903619 A SE9903619 A SE 9903619A SE 9903619 D0 SE9903619 D0 SE 9903619D0
Authority
SE
Sweden
Prior art keywords
immune responses
mediated immune
cell mediated
patient
excessive
Prior art date
Application number
SE9903619A
Other languages
English (en)
Inventor
Aake Lignell
Per Boettiger
Original Assignee
Astacarotene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astacarotene Ab filed Critical Astacarotene Ab
Priority to SE9903619A priority Critical patent/SE9903619D0/sv
Publication of SE9903619D0 publication Critical patent/SE9903619D0/sv
Priority to PCT/SE2000/001923 priority patent/WO2001024787A1/en
Priority to AU79788/00A priority patent/AU780797B2/en
Priority to CA002388785A priority patent/CA2388785A1/en
Priority to EP00970399A priority patent/EP1217996A1/en
Priority to JP2001527786A priority patent/JP5005143B2/ja
Priority to US10/088,496 priority patent/US6773708B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9903619A 1999-10-07 1999-10-07 Use and method of treatment SE9903619D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE9903619A SE9903619D0 (sv) 1999-10-07 1999-10-07 Use and method of treatment
PCT/SE2000/001923 WO2001024787A1 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
AU79788/00A AU780797B2 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
CA002388785A CA2388785A1 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
EP00970399A EP1217996A1 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections
JP2001527786A JP5005143B2 (ja) 1999-10-07 2000-10-05 自己免疫疾患、慢性ウイルス性および細胞内細菌性感染症の治療のためのアスタキサンチン等のキサントフイルの使用
US10/088,496 US6773708B1 (en) 1999-10-07 2000-10-05 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903619A SE9903619D0 (sv) 1999-10-07 1999-10-07 Use and method of treatment

Publications (1)

Publication Number Publication Date
SE9903619D0 true SE9903619D0 (sv) 1999-10-07

Family

ID=20417279

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903619A SE9903619D0 (sv) 1999-10-07 1999-10-07 Use and method of treatment

Country Status (7)

Country Link
US (1) US6773708B1 (sv)
EP (1) EP1217996A1 (sv)
JP (1) JP5005143B2 (sv)
AU (1) AU780797B2 (sv)
CA (1) CA2388785A1 (sv)
SE (1) SE9903619D0 (sv)
WO (1) WO2001024787A1 (sv)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314624D0 (en) 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
WO2005058064A1 (ja) * 2003-12-19 2005-06-30 Menicon Co., Ltd. アスタキサンチン配合ペット用食物
EP1719506A4 (en) * 2004-02-04 2011-01-26 Fuji Chem Ind Co Ltd GENETIC EXPRESSION REGULATING AGENT
BRPI0516202A (pt) 2004-09-28 2008-08-26 Chemaphor Inc produto para alimentação de um animal, uso, kit e método de preparação deste produto
JP2007238441A (ja) * 2004-12-03 2007-09-20 Fuji Chem Ind Co Ltd アスタキサンチンを有効成分とする体脂肪減少用組成物
GB0501365D0 (en) * 2005-01-21 2005-03-02 Promar As Compositions
JP2006008714A (ja) * 2005-03-17 2006-01-12 Yamaha Motor Co Ltd マトリックスメタロプロテイナーゼ阻害剤
JP2006008718A (ja) * 2005-06-03 2006-01-12 Yamaha Motor Co Ltd シクロオキシゲナーゼ活性阻害剤
JP2006008719A (ja) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd 血中過酸化脂質抑制剤
CA2551622A1 (en) * 2005-07-07 2007-01-07 H3 Formulations Ltd. Dietary supplement for enhancing skeletal muscle mass, decreasing muscleprotein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells
JP2009517482A (ja) * 2005-11-28 2009-04-30 ユーエス・ニュートラシューティカルズ・エルエルシー・ディービーエイ・ヴァレンサ・インターナショナル 藻類及び藻類抽出物の栄養補助組成物
JP2007153845A (ja) * 2005-12-07 2007-06-21 Yamaha Motor Co Ltd 脂肪蓄積抑制剤
US20070135521A1 (en) * 2005-12-14 2007-06-14 Yamaha Hatsudoki Kabushiki Kaisha Agent for Preventing Metabolic Syndrome
JP2007254411A (ja) * 2006-03-24 2007-10-04 Tokyo Univ Of Pharmacy & Life Science アグリカナーゼ産生阻害剤
US20070293568A1 (en) 2006-06-16 2007-12-20 Yamaha Hatsudoki Kabushiki Kaisha Neurocyte Protective Agent
JP2011500733A (ja) 2007-10-26 2011-01-06 ケマファー インコーポレーテッド 免疫応答を増強するための組成物および方法
CA2975313C (en) 2009-04-30 2020-06-30 Avivagen Inc. Methods and compositions for improving the health of animals
WO2010124392A1 (en) * 2009-04-30 2010-11-04 Chemaphor Inc. Methods, compositions, and kits for the treatment of inflammatory conditions
JP6580895B2 (ja) * 2014-08-08 2019-09-25 株式会社コーセー アスタキサンチン含有デスモグレイン減少剤
EP3153160B1 (en) 2015-10-08 2021-08-11 Chuen Wei Lu Use of xanthophylls for the treatment of cancers
US9572783B1 (en) 2015-10-08 2017-02-21 Chuen Wei Lu Use of xanthophylls for the treatment of cancers
CN113749050A (zh) * 2020-06-04 2021-12-07 温州医科大学 虾青素提取物治疗2型糖尿病的方法与***
IT202000032402A1 (it) * 2020-12-24 2022-06-24 Innobio S R L Composizione immunostimolante per indurre una risposta immunitaria
AU2022224703A1 (en) 2021-09-28 2023-04-13 Samuel L. Shepherd Tetraterpenes for use in cancer therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2619491B2 (ja) * 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
JPH05124958A (ja) * 1991-09-19 1993-05-21 Yukio Date 過酸化脂質低下作用を有する組成物
JPH05339148A (ja) * 1992-05-28 1993-12-21 T Knight Albert 血液脳関門を通過する物質
JPH07300421A (ja) * 1994-04-28 1995-11-14 Itano Reitou Kk 抗炎症剤
SE503336C2 (sv) * 1994-09-19 1996-05-28 Asta Carotene Ab Medel och sätt för att öka produktionen av/hos fjäderfän
US5886053A (en) * 1995-02-03 1999-03-23 Basf Aktiengesellschaft Use of carotenoids for producing drugs for the treatment of dermatoses
SE522246C2 (sv) * 1997-02-27 2004-01-27 Astacarotene Ab Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
SE511237C2 (sv) * 1997-12-16 1999-08-30 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor

Also Published As

Publication number Publication date
AU780797B2 (en) 2005-04-21
CA2388785A1 (en) 2001-04-12
EP1217996A1 (en) 2002-07-03
AU7978800A (en) 2001-05-10
US6773708B1 (en) 2004-08-10
JP5005143B2 (ja) 2012-08-22
JP2003510353A (ja) 2003-03-18
WO2001024787A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
SE9903619D0 (sv) Use and method of treatment
KR101578591B1 (ko) 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
WO2004012759B1 (de) Erythropoetin zur stimulation endothelialer voläuferzellen
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
KR101900664B1 (ko) 자가면역 및 염증성 질환에서 림프내 투여를 위한 지방-유래 중간엽 줄기 세포
SE9704693D0 (sv) Method of the prophylactic treatment of mastitis
CN102387808A (zh) 免疫增强组成物及其制造方法
IL257929B1 (en) Methods for the treatment of multiple myeloma and plasma cell leukemia using T-cell therapy
AU5198693A (en) A method of increasing adenosine excretion
CA2037779A1 (en) Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
CN106344613A (zh) 一种nk细胞原液在制备治疗皮肤病药物中的应用
NO20011667D0 (no) Behandling av dyspepsi
KR20150020112A (ko) 메트포민이 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
RU2613708C2 (ru) Способ лечения угревой болезни
Hermankova et al. The identification of interferon-γ as a key supportive factor for retinal differentiation of murine mesenchymal stem cells
CN106344612A (zh) 一种用于治疗自身免疫性皮肤病的外用药物及其制备方法和应用
DE69113802D1 (de) Anwendung von beta-alethin in zellkultur und therapie.
Mozes et al. Increased interferon production in human cells irradiated with ultraviolet light
GINGRICH et al. Anaerobic actinomycosis bovis corneal ulcer
ИММУНОСТИМУЛИРУЮЩАЯ et al. Anticancer and immunostimulatory effects of nucleoprotein fraction of Bacillus subtilis 7025 culture medium filtrate
Pordeus Immunology, Science and Public Health: the lost link
CA3241942A1 (en) Prevention and treatment of diseases using phytase
UA66331U (uk) Спосіб лікування ерозивної та виразкової форми червоного плоского лишаю слизової оболонки порожнини рота
Elliott et al. A case of infective endocarditis in a farmer caused by Streptococcus equinus